Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
Brief Summary: To evaluate vildagliptin as compared to gliclazide, given in combination with metformin in Muslim patients with type 2 diabetes fasting during Ramadan.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: add-on pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: add-on sulphonylurea | Intervention Type: DRUG; Name: add-on pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: add-on sulphonylurea; Assigned to Arm(s): 2
B: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo (high dose) | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: Placebo (low dose), Drug: BI 10773 | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo (low dose); Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo (high dose); Assigned to Arm(s): BI 10773 low dose
C: Arm Label: Vildagliptin + placebo to Gliclazide; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin, Drug: Placebo to Gliclazide | Arm Label: Gliclazide + placebo to Vildagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gliclazide, Drug: Metformin, Drug: Placebo to Vildagliptin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Gliclazide; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin, Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Gliclazide; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Vildagliptin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin
D: Arm Label: Placebo/Sitagliptin; Type: OTHER; Interventions: Drug: Placebo, Drug: Sitagliptin, Drug: Metformin, Drug: Pioglitazone | Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Pioglitazone | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Placebo/Sitagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo/Sitagliptin | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo/Sitagliptin

Answer: C